Glomerular disease: why is there a dearth of high quality clinical trials?
- 1 August 2010
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 78 (4), 337-342
- https://doi.org/10.1038/ki.2010.156
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemiaKidney International, 2009
- Mycophenolate Mofetil Treatment for IgA Nephropathy: A Meta-AnalysisAmerican Journal of Nephrology, 2008
- Researchers Facing Increasing Costs for Clinical Research, With Few SolutionsJNCI Journal of the National Cancer Institute, 2005
- Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesio11See Editorial by Haas,P. 1188.Kidney International, 2005
- Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic reviewAmerican Journal of Kidney Diseases, 2004
- The deadly risk of late referralNephrology Dialysis Transplantation, 2004
- An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticismAmerican Journal of Kidney Diseases, 2003
- Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptomsThe Lancet, 1995
- Incidence of Guillain-Barré Syndrome and Ganglioside Intake in Alcoi, SpainNeuroepidemiology, 1993